Flores José M, Kan Emily, Mooney Larissa J, Pham Huyen, Zhu Yuhui, Wolitzky-Taylor Kate, Hser Yih-Ing
University of California, Los Angeles, California.
VA Greater Los Angeles Healthcare System, Los Angeles, California.
JAACAP Open. 2024 Feb 28;2(4):231-238. doi: 10.1016/j.jaacop.2024.02.001. eCollection 2024 Dec.
Transition age youth (TAY), aged 18 to 25 years, face barriers to medication treatment for opioid use disorder (MOUD), resulting in lower retention. We evaluated OUD prevalence and MOUD receipt comparing TAY to adults aged 26 or older residing in rural settings.
Electronic health records (October 2019 to January 2021) for 36,762 patients across 6 primary care clinics involved in a large feasibility trial in US rural communities were analyzed. All clinics implemented a standardized intervention. Mixed effects logistic/linear regression estimated the odds of OUD diagnosis among all patients, and, among those with OUD, the odds of receiving MOUD and days prescribed MOUD during the 15-month study period, comparing age categories (TAY aged 18-25 years vs adults 26 years or older). Covariates included gender, race, ethnicity, mental health comorbidities, and insurance status.
OUD prevalence was 2.82% among TAY (n = 3,122) and 3.24% among adults aged 26 or older (n = 33,208). After adjusting for covariates and clustering, TAY had significantly lower odds of OUD diagnosis compared to adults 26 years or older (odds ratio = 0.58, 95% CI 0.45-0.73). There were no significant differences in MOUD receipt between age groups. Compared to adults aged 26 or older, TAY with OUD had significantly fewer MOUD days during the study, -43.81 days (-76.85 to -10.77).
Although no differences were observed in MOUD prescription receipt between TAY and adults aged 26 or older, TAY with OUD had fewer total days prescribed MOUD, indicating lower retention. Further research generalizable to rural communities is needed to assess retention among rural TAY with OUD.
Rural MOUD Telemedicine in Primary Care Phase 1 (Feasibility); https://clinicaltrials.gov/; NCT04418453.
18至25岁的转型期青年(TAY)在接受阿片类物质使用障碍药物治疗(MOUD)时面临障碍,导致治疗留存率较低。我们比较了TAY与居住在农村地区的26岁及以上成年人的阿片类物质使用障碍(OUD)患病率和MOUD接受情况。
分析了参与美国农村社区一项大型可行性试验的6家初级保健诊所中36762名患者的电子健康记录(2019年10月至2021年1月)。所有诊所都实施了标准化干预措施。混合效应逻辑/线性回归估计了所有患者中OUD诊断的几率,以及在15个月的研究期间,在患有OUD的患者中接受MOUD治疗的几率和MOUD处方天数,比较了不同年龄组(18至25岁的TAY与26岁及以上的成年人)。协变量包括性别、种族、民族、心理健康合并症和保险状况。
TAY组(n = 3122)的OUD患病率为2.82%,26岁及以上成年人组(n = 33208)为3.24%。在调整协变量和聚类后,与26岁及以上的成年人相比,TAY被诊断为OUD的几率显著更低(优势比 = 0.58,95%置信区间0.45 - 0.73)。不同年龄组在接受MOUD治疗方面没有显著差异。与26岁及以上的成年人相比,患有OUD的TAY在研究期间的MOUD天数显著更少,少43.81天(-76.85至-10.77)。
尽管在接受MOUD处方方面未观察到TAY与26岁及以上成年人之间存在差异,但患有OUD的TAY的MOUD总处方天数更少,表明治疗留存率较低。需要开展适用于农村社区的进一步研究,以评估农村地区患有OUD的TAY的治疗留存情况。
初级保健阶段1农村MOUD远程医疗(可行性);https://clinicaltrials.gov/;NCT04418453。